1st Global Advisors Inc. cut its stake in shares of Gilead Sciences Inc. (NASDAQ:GILD) by 9.1% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,169 shares of the biopharmaceutical company’s stock after selling 519 shares during the period. 1st Global Advisors Inc.’s holdings in Gilead Sciences were worth $431,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. Loomis Sayles & Co. L P boosted its stake in Gilead Sciences by 23.3% in the first quarter. Loomis Sayles & Co. L P now owns 1,591 shares of the biopharmaceutical company’s stock valued at $146,000 after buying an additional 301 shares during the period. North Star Investment Management Corp. boosted its stake in Gilead Sciences by 47.8% in the second quarter. North Star Investment Management Corp. now owns 2,165 shares of the biopharmaceutical company’s stock valued at $181,000 after buying an additional 700 shares during the period. Peoples Financial Services CORP. boosted its stake in Gilead Sciences by 30.4% in the second quarter. Peoples Financial Services CORP. now owns 2,575 shares of the biopharmaceutical company’s stock valued at $215,000 after buying an additional 600 shares during the period. iAB Financial Bank boosted its stake in Gilead Sciences by 3.3% in the second quarter. iAB Financial Bank now owns 2,750 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 87 shares during the period. Finally, BLB&B Advisors LLC purchased a new stake in Gilead Sciences during the first quarter valued at $268,000. 77.96% of the stock is owned by institutional investors and hedge funds.

Shares of Gilead Sciences Inc. (NASDAQ:GILD) traded down 0.05% during trading on Friday, reaching $78.80. 10,307,872 shares of the company’s stock were exchanged. The company’s 50-day moving average price is $79.54 and its 200 day moving average price is $86.33. The firm has a market capitalization of $103.99 billion, a PE ratio of 6.92 and a beta of 1.06. Gilead Sciences Inc. has a 52 week low of $76.67 and a 52 week high of $113.31.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Monday, July 25th. The biopharmaceutical company reported $3.08 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.02 by $0.06. The company had revenue of $7.78 billion for the quarter, compared to analysts’ expectations of $7.80 billion. Gilead Sciences had a net margin of 50.50% and a return on equity of 106.75%. The firm’s revenue was down 5.7% compared to the same quarter last year. During the same period in the prior year, the company earned $3.15 earnings per share. Analysts predict that Gilead Sciences Inc. will post $11.77 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Thursday, September 29th. Shareholders of record on Friday, September 16th will be issued a dividend of $0.47 per share. The ex-dividend date of this dividend is Wednesday, September 14th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 2.39%. Gilead Sciences’s dividend payout ratio (DPR) is 16.56%.

A number of equities analysts recently weighed in on GILD shares. Leerink Swann reaffirmed a “buy” rating and set a $120.00 price objective (down previously from $123.00) on shares of Gilead Sciences in a research report on Thursday, June 9th. Gabelli started coverage on shares of Gilead Sciences in a research report on Wednesday, June 1st. They set a “buy” rating and a $109.00 price objective for the company. Citigroup Inc. reaffirmed a “buy” rating and set a $105.00 price objective on shares of Gilead Sciences in a research report on Tuesday, May 31st. Credit Suisse Group AG reaffirmed a “buy” rating and set a $120.00 price objective on shares of Gilead Sciences in a research report on Wednesday, June 29th. Finally, Vetr cut shares of Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $95.02 price objective for the company. in a research report on Wednesday, July 6th. Nine research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and two have assigned a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $105.41.

In other Gilead Sciences news, CEO John F. Milligan sold 112,000 shares of the stock in a transaction on Tuesday, July 5th. The shares were sold at an average price of $84.33, for a total transaction of $9,444,960.00. Following the sale, the chief executive officer now directly owns 1,170,963 shares of the company’s stock, valued at $98,747,309.79. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Paul Rutherford Carter sold 2,000 shares of the stock in a transaction on Friday, July 1st. The stock was sold at an average price of $83.12, for a total transaction of $166,240.00. Following the sale, the executive vice president now directly owns 63,122 shares in the company, valued at $5,246,700.64. The disclosure for this sale can be found here. Company insiders own 1.40% of the company’s stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc is a research-based biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines in areas of unmet medical need. The Company’s principal areas of focus include human immunodeficiency virus (HIV), liver diseases, such as chronic hepatitis C virus infection and chronic hepatitis B virus infection, cardiovascular, hematology/oncology and inflammation/respiratory.

5 Day Chart for NASDAQ:GILD

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences Inc. (NASDAQ:GILD).

Receive News & Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.